Decibel Therapeutics
United States
93 articles about Decibel Therapeutics
-
Decibel Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference
9/2/2020
Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that Laurence Reid Ph.D., Chief Executive Officer of Decibel, will present at Citi's 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 1:10pm ET. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology co
-
Decibel Therapeutics to Present at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
5/11/2020
Decibel Therapeutics to Present at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss Associated with Cisplatin Chemotherapy
3/26/2020
Decibel Therapeutics , today announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs . DB-020 is being developed for the prevention of cisplatin-induced hearing loss. The
-
BioSpace Movers and Shakers, Jan. 31
1/31/2020
Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers. -
Decibel Therapeutics Announces Strategic Research Focus on Regenerative Medicine for the Inner Ear
1/29/2020
Decibel Therapeutics, a development-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced a new strategic research focus on regenerative medicine approaches for the inner ear
-
Decibel Therapeutics Announces Leadership Transition
1/29/2020
Decibel Therapeutics, a development-stage biotechnology company advancing novel therapeutics for hearing loss and balance disorders, today announced that industry veteran Laurence Reid, Ph.D., has been appointed as Decibel’s acting chief executive officer, bringing deep experience in biotech company building.
-
Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference
1/24/2020
Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.
-
Decibel Therapeutics to Provide Corporate Update at Jefferies Gene Therapy Summit
10/7/2019
Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, will provide a corporate update at the upcoming Jefferies Gene Therapy Summit in New York City on Tuesday, October 8, 2019 at 9:45 a.m. ET.
-
Biotech and pharma companies tap new members of executive leadership teams and boards.
-
Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors
6/26/2019
Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, announced the appointment of Christine Poon to its board of directors.
-
Decibel Therapeutics Selects 4G Clinical as Preferred IxRS/RTSM Provider
2/12/2019
4G Clinical today announced a partnership with Decibel Therapeutics to enable complex trial designs for the development of novel therapies for hearing and balance disorders.
-
BioSpace Movers and Shakers: Feb. 8
2/8/2019
In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles. -
Decibel Therapeutics to Present at the Association for Research in Otolaryngology (ARO) Conference
2/6/2019
Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology from February 9-13, 2019.
-
Decibel Therapeutics Bolsters Leadership Team with Appointments of Chief Medical Officer and Chief Operating Officer
2/5/2019
Decibel Therapeutics today announced the appointment of leading otolaryngologist Dr.
-
Decibel Therapeutics and Cocoon Biotech Announce Collaboration to Develop Proprietary Formulations for Delivery of Medicines to the Inner Ear
1/7/2019
Decibel Therapeutics and Cocoon Biotech announced a research collaboration to apply Cocoon's proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders
-
Among life on earth, mammals are some of the only creatures that can’t regenerate damaged hearing. Birds, frogs, fish, they all have the ability to regenerate sensory hair cells after they’re damaged.
-
Medidata and Decibel Therapeutics Announce Multi-Year Collaboration in Support of Clinical Development for Hearing Loss, Tinnitus, and Balance Disorders
9/26/2018
Decibel to Unify Data and Scale with Medidata Cloud
-
Decibel Therapeutics Research on The Role of Molecular Diversity in Neurons Critical for Hearing Published in Cell
8/2/2018
Decibel Therapeutics researchers and Johns Hopkins University professors Ulrich Mueller, Ph.D. (a Decibel co-founder) and Dwight Bergles, Ph.D., published the results of groundbreaking research which may hold the key to discovering new mechanisms behind hearing disorders and tinnitus. C
-
Venture capitalists are flexing their muscles today with the significant support of pharma and biotech companies.
-
Decibel Therapeutics Closes $55 Million Series C Financing
6/19/2018
Decibel Therapeutics announced that it has raised $55M in a Series C financing.